NMP-22, urinary cytology, and cystoscopy: A 1 year comparison study

Canadian Journal of Urology

Volumn 19, Issue 4, 2012, Pages 6345-6350

  Schlake, Anthony ^a   Crispen, Paul L ^a,b   Cap, Andrew P ^c   Atkinson, Timothy ^b   Davenport, Daniel ^a,b   Preston, David M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

^c US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

Bladder cancer; Cystoscopy; NMP 22; Urinary cytology

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; BLADDER TUMOR; CARCINOMA; COMPARATIVE STUDY; CYSTOSCOPY; CYTODIAGNOSIS; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; URINE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA; CYSTOSCOPY; CYTODIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84874406737     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts and Figures 2011. Available URL: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf. Accessed May 18, 2012.
2. National Cancer Comprehensive Cancer Network. Bladder Cancer. Practice Guidelines in Oncology v2.2012. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed May 18, 2012.
3. American Urological Association. Clinical Practice Guidelines. Guideline for Management of Non-Muscle Invasive Bladder Cancer: (Stages Ta, T1, and Tis): Update: (2007). Available from URL: http://www.auanet.org/content/clinical-practiceguidelines/clinical-guidelines.cfm?sub=bc. Accessed May 18, 2012.
4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J, Rouprêt M. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Eur Urol 2011;59(4):584-594.
5. Miller DC, Saigal CS, Litwin MS. The demographic burden of urologic diseases in America. Urol Clin North Am 2009;36(1):11-27.
6. Rania R, Pahlajani G, Ponsky LE, Agarwal A, Zippe C. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. BJU Int 2008;102(3):297-300.
7. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293(7): 810-816.
8. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol 2008;53(5):909-916.
9. Shariat SF, Marberger MJ, Lotan Y et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006;176(3):919-926.
10. Part IX (Eds): AJCC Cancer Staging Manual-Urinary Bladder. Edge SB, Byrd DR, Compton CC, et al, editors: 7th edition. New York:Springer-Verlag, 2010;497-505.
11. Nguyen C, Jones J. Defining the role of NMP22 in bladder cancer surveillance. World J Urol 2008;26(1):51-58.
12. Atsu N, Ekici S, Oge OO, Ergen A, Hascelik G, Ozen H. False positive results of NMP 22 due to hematuria. J Urol 2002;167 (2 Pt 1):555-558.
13. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162(1):53-57.
14. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 2002;168(2):465-469.
15. Lekili M, Sener E, Demir MA, Temeltas G, Müezzinoglu T, Büyüksu C. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urological Research 2004;32(2):124-128.
16. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 2009;103(10):1368-1374.
17. Yokoyama T, Sekigawa R, Hayashi T, et al. The clinical efficacy of Bladder Chek NMP22 in urothelial cancer. Rinsho Byori 2004; 52(3):199-203.
18. Casella R, Huber P, Stoffel F. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol 2000;164(6): 1926-1928.
19. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, costeffective test in patients at risk for bladder cancer. J Urol 1999; 161(1):62-65.